

## IRB

---

**From:** Ivan Satyavrata <ivan.satyavrata@gmail.com>  
**Sent:** 04 May 2026 17:20  
**To:** IRB  
**Cc:** IRBgroup  
**Subject:** Re: Decision regarding KORTUC SAE- Participant number 029- Death

**CAUTION:** This email originated from outside of the organisation. Do not click links or open attachments unless you recognize the sender and know the content is safe. This is to safeguard yourself against phishing attacks.

Support & endorsement of the SAE subcommittee's recommendation.

Ivan Satyavrata

On 4 May 2026, at 7:33 AM, IRB <irb@tmckolkata.com> wrote:

Respected members,

A Severe Adverse Event (SAE) resulting in death has been recorded for Subject No: 07/5119/029 under the CCR5119 KORTUC trial (CTRI Regd. No: CTRI/2022/02/040331).

Brief summary of the event based on the recent SAE subcommittee and IRB review:

1. Adverse Event: Myocardial infarction (Acute Coronary Syndrome)
2. Outcome: Death (Severity: Grade V)
3. Date of Onset / Death: 29 Mar 2026
4. Causality: Unlikely to be related to the trial intervention
5. IRB Decision: The patient had further disease progression and likely died as a result of the progressive disease. No compensation is recommended.

Requesting you to share your response at the earliest by 48 Hours

Sincerely

**Arkendra Narayan Choudhury**  
IRB Secretary  
Tata Medical Center, Kolkata 700160

<KORTUC 029- Death.pdf>